epileptic: Dose calibration of anti-epileptic drugs


The SANAD (Standard and New Antiepileptic Drugs) study (Marson et al, 2007) is a randomised control trial of standard and new antiepileptic drugs, comparing effects on longer term clinical outcomes. The data consists of longitudinal measurements of calibrated dose for the groups randomised to a standard drug (CBZ) and a new drug (LTG). The objective of the analysis is to investigate the effect of drug titration on the relative effects of LTG and CBZ on treatment failure (withdrawal of the randomized drug). There are several baseline covariates available, and also data on the time to withdrawal from randomized drug.




This is a data frame in the unbalanced format, that is, with one row per observation. The data consists of columns for patient identifier, time of measurement, calibrated dose, baseline covariates, and survival data. The column names are identified as follows:


SANAD Trial - University of Liverpool


Williamson P.R. , Kolamunnage-Dona R, Philipson P, Marson A. G. Joint modelling of longitudinal and competing risks data. Statistics in Medicine, . 27, No. 30. (2008), pp. 6426-6438.

Questions? Problems? Suggestions? or email at ian@mutexlabs.com.

All documentation is copyright its authors; we didn't write any of that.